Equities researchers at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Performance
Shares of NASDAQ LPCN opened at $4.80 on Friday. The firm’s 50 day moving average price is $4.58 and its 200-day moving average price is $3.57. The company has a market cap of $25.67 million, a PE ratio of -1.57 and a beta of 1.05. Lipocine has a 52-week low of $2.31 and a 52-week high of $7.15.
Lipocine (NASDAQ:LPCN – Get Free Report) last issued its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.11. The company had revenue of $0.22 million during the quarter. On average, analysts forecast that Lipocine will post -1.49 earnings per share for the current fiscal year.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Recommended Stories
- Five stocks we like better than Lipocine
- Buy P&G Now, Before It Sets A New All-Time High
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- Following Congress Stock Trades
- MarketBeat Week in Review – 4/22 – 4/26
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
